Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment

Inclusion Criteria: * Signed and dated informed consent (ICF): a written informed consent must be obtained prior to any study related procedure being performed * Male and female out-patients aged 18 to 80 years * GERD diagnosis confirmed through a validated questionnaire (GERDQ score ≥ 8). * EGD endoscopy performed within 1 year before screening * Patients in continuous or intermittent treatment with PPI for at least 1 year and continuously for at least 4 weeks prior to study entry * Patients not fully satisfied with current PPI treatment (1-3 score on 5-points Likert scale) Exclusion Criteria: * Dyspeptic patients or patients with overlapping symptoms with GI diseases other than GERD * Histological evidence of Barrett's oesophagus \> 1 cm in EGD endoscopy * Peptic stricture in EGD endoscopy * Concurrent findings in the EGD endoscopy that might interfere with the participation to the study (e.g cancer, peptic ulcer) as judged by the investigator * Known impaired kidney or liver function at screening * Presence of any relevant severe condition or clinically relevant abnormal parameters that in the opinion of the investigator may interfere with the participation to the study * Medication use (including H2 antagonists, alginates, baclofen, NSAIDS, prokinetics, antidepressants) that may interfere with GERD symptom assessment within 2 weeks before the start of the study or during the study * Pregnancy or breast-feeding * Females of childbearing potential not employing adequate …